Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

Oncology (Switzerland)

Volumn 45, Issue 5, 1988, Pages 350-353

  Alonso Munoz M C ^{a,b,c,d,e,f,g}   Ojeda Gonzalez M B ^{a,b,c,d,e,f,g}   Beltran Fabregat, M ^{a,b,c,d,e,f,g}   Dorca Ribugent, J ^{a,b,c,d,e,f,g}   Lopez Lopez L ^{a,b,c,d,e,f,g}   Borras Balada J ^{a,b,c,d,e,f,g}   Cardenal Alemany, F ^{a,b,c,d,e,f,g}   Gomez Batiste X ^{a,b,c,d,e,f,g}   Fabregat Mayol, J ^{a,b,c,d,e,f,g}   Viladiu Quemada, P ^{a,b,c,d,e,f,g}  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Hospital de Santa Caterina ^*  (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d HOSPITAL DE L ESPERANÇA   (Spain)

^e Universidade de Lleida   (Spain)

^f Hospital Sant Jaume de Calella   (Spain)

^g Hospital Cruz Roja   (Spain)

Author keywords

Aminoglutethimide; Breast carcinoma; Hormonal therapy; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; HYDROCORTISONE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; STOMACH HEMORRHAGE;

ADULT; AGED; AMINOGLUTETHIMIDE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMAN; MENOPAUSE; MIDDLE AGE; RANDOM ALLOCATION; TAMOXIFEN;

EID: 0023695006     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000226639     Document Type: Article

References (21)

1. Cole M P, Jons CTA, Todd IDH: A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI, 46474. Br J Cancer 1971;25:270-275.
2. Mouridsen H. Palshoff T. Pattcsson J, et al: Tamoxifen in advanced breast cancer. Cancer Treat Rev 1978;5:131-141.
3. Viladiu P, Bosch FX, Benito E. et al: Antiestrogen tamoxifen in the treatment of advanced breast cancer. A series of 31 patients. Cancer Treat Rep 1977;61:899-900.
4. Lippman M E: Antiestrogen therapy of breast cancer. Semin Oncol 1983; 10(suppl 4): 11-19.
5. Cash R, Brough A J, Cohen M N P. et al: Aminoglutethimide as an inhibitor of steroidogenesis. Mechanism of action and therapeutic trial. J Clin Endocrinol McLab 1967;27:1239-1248.
6. Cohen MP, Foc F’P: Aminoglutethimide inhibition of adrenal dismolasc activity. ProcSoc Exp Biol Med 1969;127:1086-1090.
7. Santen RJ, Sanfrer SS, Davis B. et al: Aminoglutethimide inhibits extraglandular oestrogen productions in postmenopausal women with breast carcinoma. J Clin Endocrino Metab 1978:47:1257-1265.
8. Santen RJ. Wells SA: The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 1980:46:1066-1074.
9. Smith IE. Harris AL. Morgan M. et al: Tamoxifen versus aminoglutethimide in the treatment of metastatic breast cancer. A control randomised crossover trial. Br Med J 1981: 283: 1432-1434.
10. Lipton A, Harvey HA, Santen RJ. et al: Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982:42(suppl):3434-3436.
11. Harvey H A. Lipton A. White DS, et al: Crossover comparison of tamoxifen and aminoglutcthimide in advanced breast cancer. Cancer Res 1982;42(suppl):3451 3453.
12. Hayward JL, Carbone PP, Henson JC. et al: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977:13:89-94.
13. Peto R, Pina MC, Armitage P. et al: Designs and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976:34:585-612.
14. Rubens RD: The addition of prednisolone to tamoxifen to increase remission rate; in Stoll BA (ed): Reviews on Endocrine-Related Cancer. London. ICI Pharmaceuticals Division, 1981, vol 10. p 29.
15. Torney DC, Lippman ME, Edwards MK. et al: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983;98:139-144.
16. Powles TJ, Ford HT, Nash AG. et al: Treatment of disseminated breast cancer with tamoxifen, aminoglutcthimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet 1984;i: 1369-1373.
17. Ingle JN, Green SJ, Ahmann DL. et al: Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortinonc in women with metastatic breast cancer. J Clin Oncol 1986:4:958-964.
18. Ragaz J: Aminoglutethimide in breast cancer; in Nagel GA, Santen RJ (eds): Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer. Bern, Huber, 1984, pp 123-125.
19. Smith IE, Flarris AL, Morgan M, et al: Tamoxifen versus aminoglutethimide versus combined tamoxifen and amino-glutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982;42(suppl):3430-3433.
20. Harvey HA, Lipton A, Santen RJ: Clinical studies with amino-glutethimide in advanced carcinoma; in Nagel GA, Santen RJ (eds): Aminoglutethimide as an Aromatase Inhibitor in the Treatment of Cancer. Bern. Huber. 1984, pp 74-89.
21. Twycross RG: Continuing in terminal case: An overview; in Bonico JJ. Ventafridda V (eds): Advances in Pain Research and Therapy. New York, Raven Press. 1979, vol 2, pp 617-633.